Michael Cupo, Ph.D.

Manager, Clinical Development
GlaxoSmithKline
Collegeville, PA, United States

GlaxoSmithKline (Employee)

Presentation(s):

• 75 - High Rates of Virologic Suppression with DTG/3TC in Newly Diagnosed Adults with HIV-1 Infection and Baseline Viral Load >500,000 c/mL: 48-Week Subgroup Analysis of the STAT Study

  On Demand